Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03801148 · ClinicalTrials.gov registry record · Phase 1
A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release Capsules
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 122
- Enrollment target
NCT03801148: Completed Phase 1 study, sponsored by Takeda.
NCT03801148 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 122 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (103% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03801148, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 122 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the BA of 30 or 60 milligram (mg) dexlansoprazole capsule manufactured at TOB (Takeda GmbH Plant Oranienburg) to the corresponding 30 or 60 mg dexlansoprazole manufactured at TPC (Takeda Pharmaceutical Company Ltd.).
Interventions
- DRUG 30 mg dexlansoprazole capsules manufactured at TOB
- DRUG 30 mg dexlansoprazole capsules manufactured at TPC
- DRUG 60 mg dexlansoprazole capsules manufactured at TOB
- DRUG 60 mg dexlansoprazole capsules manufactured at TPC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2019-01-10 |
| Est. Completion | 2019-04-09 |
| Phase | Phase 1 |
What the finished NCT03801148 record still lists
NCT03801148 is an interventional study that assigns participants to a tested intervention. The registered 122 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (103% higher).
The record links to 0 conditions, and to 4 interventions - of which 30 mg dexlansoprazole capsules manufactured at TOB is the first listed.
NCT03801148 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03801148 about?
NCT03801148 is a clinical study titled "A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release Capsules". The purpose of this study is to assess the BA of 30 or 60 milligram (mg) dexlansoprazole capsule manufactured at TOB (Takeda GmbH Plant Oranienburg) to the corresponding 30 or 60 mg dexlansoprazole manufactured at TPC (Takeda Pharmaceutical Company Ltd.).
What is the current status of trial NCT03801148?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 122 participants. The study started on 2019-01-10. Estimated completion is 2019-04-09.
What interventions are being tested in trial NCT03801148?
The interventions under investigation include: 30 mg dexlansoprazole capsules manufactured at TOB (DRUG), 30 mg dexlansoprazole capsules manufactured at TPC (DRUG), 60 mg dexlansoprazole capsules manufactured at TOB (DRUG), 60 mg dexlansoprazole capsules manufactured at TPC (DRUG).
Who is sponsoring clinical trial NCT03801148?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03801148's enrollment target sits among peer trials
122 475th of 2000 higher than 1,525 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03363373 · 122 participants · Phase 2
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
- NCT03463954 · 122 participants · NA
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
- NCT04503265 · 122 participants · Phase 1
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
- NCT04700527 · 122 participants · Phase 1
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI